Combination of Serratus Anterior and Pectoral Nerve Blocks (PECS II) as Main Anesthetic Method in Breast Cancer Surgery

July 7, 2023 updated by: Gamze Ertas, Samsun University

Feasibilty of Serratus Anterior and Pectoral Nerve Blocks (PECS II) Combination as Main Anesthetic Method in Breast Cancer Surgery Patients

Aim of this study is to determine the success of combined serratus anterior and PECS-2 block as the main anesthetic method in breast cancer surgery and also to investigate the patient acceptability of this combination and its relationship with surgeon satisfaction.

Study Overview

Status

Completed

Conditions

Detailed Description

Breast conserving surgery or mastectomy is applied in the surgical treatment of breast cancer. Axillary interventions range from sentinal lymph node biopsy to lymph node dissection. Clinically significant acute pain develops following breast surgery in 35% of patients.

Today, regional anesthesia is widely used as an opioid-sparing strategy in the treatment of acute postoperative pain. New fascial plane blocks have been developed as alternative or complementary techniques for chest wall analgesia, including pectoral nerve blocks (PECS1-2) and serratus plane block.

In order to reduce the risk of perioperative morbidity and mortality and to meet the patient demand, the demand for awake surgery is increasing in institutions.

Therefore, a prospective observational case series was conducted to explain the efficacy, patient acceptability, and surgeon satisfaction of combined serratus anterior and PECS-2 block as the main anesthetic method for breast cancer surgery.

Study Type

Observational

Enrollment (Actual)

17

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Samsun, Turkey, 55040
        • Samsun University
    • Ilkadım
      • Samsun, Ilkadım, Turkey, 55100
        • Samsun University

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Female patients aged 18-80 years with breast cancer

Description

Inclusion Criteria:

  • Patients between the ages of 18-80 and ASA I-III who will undergo unilateral breast cancer surgery will be included in the study.

Exclusion Criteria:

  • Patients with previous breast surgery other than excisional biopsy,
  • coagulopathy,
  • bleeding disease,
  • local infection at the injection site,
  • history of local anesthetic allergy,
  • psychiatric disease (depression, mania, schizophrenia or antipsychotic drug use),
  • history of opioid use for more than 4 weeks
  • Patients with body mass index (BMI) >40kg/m2 and
  • chest deformity (pectus excavatum and pectus carinatum) will be excluded from the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Sufficient surgical anesthesia
Time Frame: up to 30 minutes
After confirming the sensory block in the surgical area with the post-procedure pinpirick test, successful completion of the surgical procedure 'without the need for deep sedoanalgesia' will be considered 'sufficient surgical anesthesia'.
up to 30 minutes

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Pain scores on the Numeric Rating Scale (NRS)
Time Frame: up to 24 hours
Changes in Numeric Rating Scale (NRS) at rest and on movement will be recorded at intervals. NRS is a unidimensional measure of pain intensity in adults. The NRS is a segmented numeric version of the visual analog scale (VAS) in which a respondent selects a whole number (0-10 integers) that best reflects the intensity of his/her pain. The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").
up to 24 hours
Quality of recovery 15 scale
Time Frame: up to 24 hours
Postoperative Quality of Recovery 15 in Turkish scale
up to 24 hours
analgesic consumption
Time Frame: up to 24 hours
In the postoperative period, patients will be given opioids according to their pain density with a patient-controlled device, and the daily Morphine consumption in Patient Controlled Analgesia device will be collected
up to 24 hours
modified Wilson Sedation Scale
Time Frame: up to 2 hours
  1. Oriente, eyes may be closed, but says his name, answers where he is
  2. Sleepy, eyes may be closed, can be warned when called by name
  3. Can be stimulated by mild physical stimulation (earlobe)
  4. Cannot be stimulated by mild physical stimulation
up to 2 hours
quality of anesthesia
Time Frame: up to 2 hours

Are you satisfied with the anesthesia? Would you like to have surgery with the same technique again? Would you recommend it to others?

  1. Extremely satisfied,
  2. Satisfied,
  3. Neither satisfied nor dissatisfied,
  4. Not satisfied,
  5. It will be calculated by responding as highly dissatisfied.
up to 2 hours
scaling working conditions
Time Frame: up to 2 hours

Working conditions scaling

Indistinguishable from general anesthesia A little challenging/enough It will be determined by choosing one of the overly challenging/inadequate options.

up to 2 hours

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: gamze MD ertaş, specialist, Samsun University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

July 7, 2022

Primary Completion (Actual)

July 7, 2023

Study Completion (Actual)

July 7, 2023

Study Registration Dates

First Submitted

June 13, 2022

First Submitted That Met QC Criteria

June 16, 2022

First Posted (Actual)

June 22, 2022

Study Record Updates

Last Update Posted (Actual)

July 10, 2023

Last Update Submitted That Met QC Criteria

July 7, 2023

Last Verified

July 1, 2023

More Information

Terms related to this study

Other Study ID Numbers

  • SamsunU (Other Identifier: Samsun university)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Subscribe